A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.

more

Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

Health ministry approves new tuberculosis drug

“New Delhi: Perturbed by the increasing number of multi-drug resistant (MDR) and extensive drug resistant (XDR) tuberculosis cases in India, the health ministry has approved the use of a new drug in the treatment of such cases.

The technical group on tuberculosis in the ministry of health has given approval to Delamanid, which is in its phase 3 clinical trials.

“We are losing a lot of patients to XDR and MDR tuberculosis. We need more than one drug for treating patients in the backdrop of increasing drug resistance in patients. Delmanid proved to be a good alternative. We will initially conduct a trial with this drug on over 400 patients in a controlled manner,” said Jagdish Prasad, director general of health services in the ministry.

“Currently, around 50% of patients don’t respond to tuberculosis treatment. Delamanid has proved effective in many clinical trials in South Africa and Japan. Taking a cue from this, we are expecting that over 70-80% patients will respond to tuberculosis treatment,” he said.”

To read the full article click here.

Recent News and Announcements

STREAM MDR-TB Clinical Trial: Results of comparison of 9-Month Treatment Regimen to 20-24 month regimen.

Dr. I.D. Rusen, MD, of the MRC presented the preliminary results from Stage 1 of the STREAM randomized clinical trial on Thursday, December 14th from 10:00 – 11:00 EST (16:00 – 17:00 CET; 17:00 – 18:00 SAST). The STREAM Clinical Trial team, including Andrew Nunn and Patrick Philips (Medical Research Council’s Clinical Trials Unit at UCL) and I.D. Rusen […]

Drug-Resistant Tuberculosis to Increase in 4 High-Burden Countries

Drug-resistant tuberculosis cases are on the rise in Russia, India, the Philippines, and South Africa and expected to increase through 2040. Additional strategies to prevent transmission will be necessary to stop multidrug-resistant or extensively drug-resistant tuberculosis in countries with a high burden of MDR tuberculosis. Watch the video found here to find out more.

New TB drugs are more effective and may be less toxic. Why are they still unavailable?

“The start of 2017 saw concern over a sharp increase in the rise of drug-resistant TB in South Africa. TB is killing millions each year. Last week, Médecins Sans Frontières published promising early data on the use of two new TB drugs, delamanid and bedaquiline, among patients living with drug-resistant TB in Khayelitsha, Cape Town. […]

STREAM clinical trial results provide vital insight into nine-month treatment regimen for multidrug-resistant tuberculosis

“Preliminary results – released at the 48th Union Conference on Lung Health – from Stage 1 of the STREAM randomized clinical trial show that the nine-month treatment regimen being tested achieved favorable outcomes in almost 80 percent of those treated.The results suggest the nine-month regimen is very close to the effectiveness of the 20-24 month regimen […]

New Treatments for Drug-Resistant TB Get a Boost

Article by Betsy McKay, published in the Wall Street Journal, 13 Oct 2017 7:00 A.M. ET New research released this week bolsters the case for more effective, less toxic and shorter treatment regimens for drug-resistant tuberculosis, offering hope for patients suffering from a disease that is notoriously difficult to treat.   The three separate studies […]

Event Calendar

Social Media